For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
The goal of this clinical research study is to learn if the combination of cladribine, idarubicin, and cytarabine can help to control AML, high risk MDS, and/or CML in blast phase. The safety of these drugs will also be studied.
Thu, 05/01/2014 to Tue, 05/01/2018
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Drug: Cladribine Induction Phase: Cladribine 5 mg/m2/day by vein on Days 1 - 5. Consolidation Phase: Cladribine 5 mg/m2/day by vein on Days 1 - 3. Other Names: Leustatin 2-CdA Drug: Cytarabine Induction Phase: Cytarabine 1 gram/m2/day by vein on Days 1 - 5. Consolidation Phase: Cytarabine 0.75 gram/m2/day by vein on Days 1 - 3. Other Names: Ara-C Cytosar DepoCyt Cytosine Arabinosine Hydrochloride Drug: Idarubicin Induction Phase: Idarubicin 10 mg/m2/day by vein on Days 1 - 3. Consolidation Phase: Idarubicin 8 mg/m2/day by vein on Days 1 - 2. Behavioral: Phone Calls After last dose of study drug, participant called every 6 -12 months by a member of the study staff to ask about any side effects they may be having. The phone call should take about 5-10 minutes.